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Brain pathology of Lafora disease : fine structural changes of
Lafora (polyglucosan) bodies in the developing phase of the formation
Noriaki Yoshimura１）
Abstract
Lafora disease（LD）is an autosomal recessively inheritable neurodegeneration due to glycogen 
metabolic disorder, characterized pathologically by the presence of Lafora bodies（LB）（called 
polyglucosan bodies; malformed insoluble glucose polymers）in CNS neurons and cells in many other 
organs.  Recently, it has become evident that about 90% of cases of LD are caused by mutations in 
either the EPM2A（laforin）or the EPM2B（malin）gene.  Few previous EM studies have observed LB 
in the developing phase in detail.  This study aimed at obtaining key ﬁndings that may reveal molecular 
events involved in the disease mechanisms underlying the morphology, by EM observations on LB in 
brain tissue from a previously reported case of LD.  The observations revealed that the two main 
components of LB, i.e.  poorly branched, irregular ﬁne ﬁlaments and amorphous small dense granules, 
were distributed sparsely in the LB in the early phase, whereas in the developing phase the fine 
ﬁlaments were innumerable together with a substantial number of dense granules and polysomes along 
with some lysosomes and no apparent autophagosomes.  They intermingled and formed LB.  In the 
developed phase, cored LB consisted of aggregates of dense granules forming the core and radially 
arranged ﬁlaments forming the outer rim.  Recently, it has been reported that the lack of laforin-malin 
complexes causes the dysfunction of autophagy, which plays a primary role in the LB formation.  The 
lack of Laforin-malin complexes and impaired autophagy for aggresome clearance were discussed.  In 
conclusion, the ﬁne structural changes of LB in the developing phase could be the key ﬁndings that 
link to the molecular mechanisms of not only LB but also LD.  
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Introduction
　　Lafora disease（LD）is an autosomal recessively 
inheritable neurodegenerative disorder, characterized 
clinically by myoclonus, epileptic convulsions and 
progressive mental deterioration.  The disease manifests 
with stimulus-sensitive tonic-clonic, grand mal, visual 
and myoclonic seizures which rapidly progress severe 
myoclonic epilepsy and status epilepticus, resulting in 
dementia, muscle wasting and respiratory failure.  The 
disease mostly occurs between the age of 10 and 17 and 
death follows about 10 years after the onset（Anraku 
and Hakusui 1989; DiMauro,1996; Inenaga and 
Anraku1974; Lafora and Glueck, 1911; Naito and 
Oyanagi,1989; Seitelberger, 1968）.  The disease is also 
characterized histologically by the presence of 
intracytoplasmic periodic acid Schiff-positive 
inclusions known as Lafora bodies（LB）in many 
tissues, such as the brain, liver, myocardium, skeletal 
muscle and skin（Adams and Lee, 1982; DiMauro, 
1996; Inanaga and Anraku 1974; Thom et al, 2008）. 
Their histological appearance differs depending on 
tissues affected（Adams and Lee, 1982; Seitelberger, 
1968; Thom et al, 2008）: LB in the brain are seen 
predominantly in perikarya and dendrites of neurons. 
The majority of the LB stained strongly with periodic 
acid-Schiff（PAS）have a darkly stained core and lightly 
stained radiating shells.  The larger LB are invariably 
perikaryonal in a distribution similar to the endoplasmic 
reticulum（ER）, and the sandgrain-like granules which 
− 20 −
are also revealed by PAS staining are concentrated 
mostly in small neuronal dendritic processes and on 
rare occasion in axons（Adams and Lee, 1982; Iwata 
1986; Seitelberger, 1968; Van Heycop Ten Ham, 
1974;Yagishita, 1994; Yoshimura et al, 1999）.  LB are 
found in other organs, most prominently in the liver, 
heart, skeletal muscle, and moderately in smooth 
muscle of the alimentary tract（Yoshimura et al, 1999）, 
in addition to the sweat gland duct cells in the skin
（Carpenter and Karpati 1981）.
　　Cytochemical studies indicated that LB contained 
a substantial amount of a complex carbohydrate, only a 
small portion of which was consistent with acid 
mucopolysuccharides（Seitelberger, 1968; Adams and 
Lee 1982）.  In addition, a protein moiety was demonstrated, 
which appeared to be sensitive to chymotripsin and 
pepsin, but more speciﬁcally to the latter（Gambetti et 
al, 1971; Nikaido et al, 1971）.  LB contain 80-93% 
polyglucosan and 6% proteins depending on tissues, 
although the natures of the proteins are mostly unknown
（Yokoi et al, 1968; Sakai et al, 1970）.  Polyglucosans 
are malformed glycogen molecules（glucose polymers）
that appear as peculiar linear strands defective of 
normal branching（DePaoli-Roach et al, 2010）. 
Resembling amylopectin, polyglucosans are poorly 
soluble hence precipitate inside cells.   
　　LD is caused by mutations in either EPM2A gene 
present on 6q24, encoding laforin（Minassian et al, 
1998; Serratosa et al, 1999）, or EPM2B gene located 
on 6p22.3 which encodes malin（Chan et al, 2003; Chan 
et al, 2003）, although there is evidence for a third locus
（Chan et al, 2004）.  Laforin is a glycogen phosphatase
（in detail, a dual speciﬁcity protein phosphatase with a 
functional carbohydrate-binding domain）.  Malin is an 
E3-ubiquitin ligase having RING ﬁnger domain at the 
N-terminus.  However, the disease mechanisms that are 
brought about by mutations in these two genes are 
poorly understood.  Therefore, it is necessary to elucidate 
what the structural and functional changes are expressed 
on cell and tissue structures in vivo, due to the defective 
gene product.  The ﬁne structural changes of LB have 
been reported by many authors so far（Anraku and 
Hakusui, 1989; Collins et al, 1968; Namba, 1971; Kotorii 
et al, 1974; Van Heycop Ten Ham, 1974; Vanderhaeghen, 
1971; Cajal  et al, 1974; Gambetti et al, 1971; Ishihara 
et al, 1987; Oyanagi, 1992; Van Hoof and Hageman-
Bal, 1967; Yoshimura et al, 1999）.  Almost all of them, 
however, have reported on those of matured/developed 
phase of LB rather than their early or developing phase. 
The purpose of the present study is to obtain key 
ﬁndings that may reveal molecular events involved in 
the disease mechanisms underlying the morphology.  
Materials and Methods
　　A male patient with Lafora disease with a 17-year 
clinical course, aged 30 at death was autopsied 8 hours 
after death.  The brain showed no gross abnormality 
except for a slight increase in weight（1,500g）（Fig. 
1a, b）.  The autopsy ﬁndings of all organs including the 
CNS, together with fine structural changes and 
immunoreactivities of LB in brain tissue against 
ubiquitin and tau antibodies were reported previously
（Yoshimura et al.  1999）.  A histological reexamination 
was made by LM using slides stained with H&E, 
Kluever-Barrera, Bodian, periodic acid-Schiff（PAS）, 
and PAS after diastase digestion methods.  For electron 
microscopy（EM）, epon-embedded tissue-piece blocks 
of frontal（F1）and temporal（T2）cortices and those of 
the globus pallidus and substantia nigra were selected. 
These epon-embedded blocks had been made 
immediately after the autopsy.  Semi-thin sections 
stained with 1% toluidine blue solution were made. 
After observing the toluidin blue stained slides, 
ultrathin sections which were obtained by using a 
Porter-Blum ultramicrotome（RMC; MT-6000）were 
double-stained with uranyl acetate and lead citrate. 
They were examined using an H-600 electron microscope
（Hitachi, Tokyo, Japan）at 80kV.  
Results
　　After histological examinations described above, 
LB formed in the perikaryon were classified into 3 
phases based on the evolution:（1）the early phase
（Figs.1c, d, arrowheads）exhibits LB having a small 
and vague contour, a moderate reactivity to PAS, and no 
displacement of the nucleus nor enlargement of the cell 
body, （2）the developing phase（Figs.1c, d arrows）
indicates LB that have a somewhat vague contour, a 
moderate reactivity to PAS, and no distinct core nor 
marked displacement of the nucleus,（3）the developed 
phase（Fig.3a, b double-arrows; Figs.  5c and e）shows 
enlarged cored or coreless LB having a distinct contour, 
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usually a strong reactivity to PAS and marked 
displacement and deformity of the nucleus with striking 
distension of the cell body.  　
EM observations of LB in the early phase
　　The present study dealt with ultrastructural 
observations of LB mainly in the developing phase. 
Before this, however, we ﬁrst observed LB in the early 
phase.  The ultrastructural changes were very similar 
to those of LB in the developing phase in that LB 
appeared as a cytoplasmic mass with no limiting 
membrane and consisted of two main components in 
various proportions; fine irregular filaments and 
amorphous and electron-dense granules showing 
irregular and rather sparse distribution in the 
cytoplasm of low density.
EM observations of LB in the developing phase
　　Electron microscopy of nerve cells bearing LB in 
the developing phase regularly showed that the 
perikaryon was occupied by a large mass of cytoplasm 
of low density containing two main components in 
various proportions; the ﬁne ﬁlaments, approximately 6 
nm in diameter, were irregular and occasionally 
branched, although such branches were short and only 
traceable up to a short distance.  They were frequently 
continuous with small dense granules which varied in 
size and shape.  The cell nucleus was somewhat 
displaced toward the cell membrane, along with 
organella such as rough endoplasmic reticulum（rER）, 
polysomes, mitochondria and vesicles.  At a glance, the 
cytoplasm consisted of innumerable, short and very ﬁne 
Fig.1 1a.  Lateral view of the brain showing no gross abnormality.
1b.  Serial coronal sections of the right cerebral hemisphere showing no remarkable change.
1c & d.  Histology of the superior olivary nucleus showing various phases of LB:early phase （arrow）, developing 
phase（arrowhead）, and developed phase（2 arrowheads）.
1c.  PAS stain  x 530,  1d. PAS stain  x 530.
1e & f.  Histology of LB in the perikaryon of nerve cells in the frontal cortex.
1e.  PAS stain x 530, 1f. PAS stain x 530.
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Fig.2 Electron micrograph of a LB in the developing phase illustrating that a newly-formed cytoplasmic 
mass with no limiting membrane occupies the perikaryon pressing  aside the preexisting cytoplasm 
containing mitochondria, rERs  polysomes（p） and lysosomes（ly） toward the cell membrane.  The 
body consists of two main components in various proportions: fine irregular filaments（arrows）and 
amorphous dense granules（arrowheads）exhibiting irregular distribution in the newly-formed 
cytoplasm of low density. 
 x  13,600.     Inset  PAS stain   x  530.
− 23 −
filaments intermingling and running in random 
directions（Fig.2-4）.  More precise observations, 
however, revealed that a substantial number of those 
filaments tended to form a semi-parallel arrangement 
similar to that of pine needles. （Figs.3-5a）.  In the 
transitional zone between the superficial area of the 
newly-formed and the pre-existing cytoplasm, there 
was degradation of rER associated with an increase in 
their ﬂuffy pattern of short ﬁlaments（Figs.2-4）.  From 
the surface to the center of LB, there were short fine 
filaments, two to several of them arranged in a semi-
parallel fashion intermingling and running in random 
directions.  In addition, small dense granules, polysomes, 
small pieces of rER, lysosomes, and multivesicular 
bodies were present here and there（Figs.2-4）. 
However, it was difficult to detect autophagosomes, 
centrioles and mitochondria in the depth of the LB.    In 
the center of the LB there was sometimes a sign of 
accumulation of the small dense granules which would 
come to form a central core（Figs.2 and 4b ）.
EM observations of the LB in the developed phase
　　The most representative profile of cored LB 
formed in the perikaryon（Figs.1c-f, Figs.5b and d）
often showed perikaryonal distension and marked 
Fig.3 3a. Electron micrograph of the left part of the LB in Fig.2, illustrating that the newly-formed 
cytoplasm consists of fine filaments intermingling with and running in random directions, 
associated with scarce presence of small dense granules.  In addition, note the concurrent presence 
of many polysomes（p）, small rERs, multivesicular bodies（mv）, and probable lysosomes（ly）. 
x    20,000.
3b. Electron micrograph of the right upper part of the LB in Fig.  2, demonstrating that some of those 
filaments form a semi-parallel arrangement similar to that of “pine-needles”.
 x    32,400. 
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nuclear  d i sp lacement  wi th  deformi ty,  which 
corresponded to the LB in the developed phase.  In the 
cored LB, the size of the core varied from null or pin-
point size to full size appearing to completely occupy 
the LB.  Thus most of the developed/matured LB 
formed in the perikaryon had a dense core（and/or a 
ring）and a light outer rim（Figs.1e and f）.  The bigger 
and the denser the core became, the more developed/ 
matured LB seemed to become.  Those perikaryonal LB 
whose cores showed stronger reaction to PAS appeared 
to be more developed/matured than those whose cores 
showed a weak reaction.  
(a) The cored LB
　　Electron microscopy disclosed that cored LB were 
an increased mass of cytoplasm with no limiting 
membrane and consisted of two main components in 
various proportions; irregular ﬁlaments and small dense 
granules.  The filaments seemed a little thicker and 
harder than those seen in the LD in the early and 
developing phases.  The filaments,  measuring 
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Fig.4 4a. Electron micrograph of the left upper part of the LB in Fig.2, depicting that increased fine 
filaments（arrows） form a semi-parallel arrangement intermingling with cytoplasm which 
contains many polysomes（p）,  small pieces of rER and lysosomes（ly）.     
 x    33,400
4b. Electron micrograph of the lower part of the LB in Fig.2, exhibiting innumerably increased fine 
filaments which intermingle and run in random directions.  The filaments（arrows） frequently 
form a semi-parallel arrangement, which are often continuous with the small dense granules
（arrowheads）.  The cytoplasm containing many polysomes（p）, small rER, multivesicular bodies 
（mv）and lysosomes（ly）.
                                             x    25,300
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Fig.5 5a. Electron micrograph of a cored LB in the developed phase demonstrating that the poorly 
branched filaments measured about 8 nm in diameter, frequently form a semi-parallel 
arrangement（arrowheads）, some of which resemble that of “pine-needles”.  Most of the 
filaments（arrows）seem to appear from small dense granules（g）and their aggregation 
forming a huge central core（cc）,  and some of the filaments also have connections with 
rER and polysomes（p）. x   34,000
5b. Histology of the frontal cortex exhibiting a pin-point cored homogeneous LB in the 
developed phase.  Note 3 nerve cells having marked displacement and deformity of the 
nucleus（arrowheads）. PAS stain   x   530
5c. Electron micrograph demonstrating that a light homogeneous LB with a pin-point core in 
the developed phase consists of densely increased fine filaments all over the LB, associated 
with a focal accumulation of aggregated small dense granules in the center of the body, 
which may correspond to a pin-point core under LM.    x   25,000
5d. Electron micrograph of a ring-cored LB in the developed phase demonstrating that light 
PAS-reactive ring-zones exclusively consist of densely increased fine filaments and strong 
PAS-reactive zones are composed of densely increased filaments plus deposition of 
aggregated dense granules in various degrees, which are parallel to the intensity of the 
PAS-reaction of the ring.  x   15,000.
 Inset  shows a ringed LB in the developed phase. PAS stain   x   530. 
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approximately 8 nm in diameter, were irregular and 
occasionally branched, although such branches were 
short and only traceable up to some distance.  The 
filaments were frequently continuous with the small 
dense granules which varied from small flocculent 
deposits to large conﬂuent dense granule aggregations, 
which had gradual transition to a huge dense core of LB
（Fig. 5a）.  Cored LB had a dense core and a light outer 
rim（Figs.1e, f）.  Because the filaments intermingled 
with a large confluent dense granular material in the 
core of the LB, only in the rim were the filaments 
recognized as being arranged radially.  As were already 
observed in the LB in the developing phase（Fig.2-4）, 
some of those ﬁlaments tended to form a semi-parallel 
arrangement similar to that of pine needles.  On the 
outer side of those radial arrangements, there were 
some gatherings of rER whose membranes and 
polysomes were often continuous with the filaments
（Fig. 5a）.  
(b) Light homogeneous LB 
　　Light homogeneous LB exhibited that the entire 
area of the pale body consisted of only compactly 
intermingled filaments innumerably increased in 
number, associated scarcely with the small dense 
granules.  
　　The light homogeneous LB with a pin-point core 
showed that the entire area of the pale body consisted 
of only compactly intermingled ﬁlaments innumerably 
increased in number, and limited in the central area 
only there was an aggregation of irregularly fused dense 
granules forming a micro-core that would correspond to 
a pin-point core of the LB under LM（Figs.5c）.  
(c) Dark homogeneous LB
　　In contrast, the dark homogeneous LB were 
composed of compactly intermingled filaments 
innumerably increased in number, associated with 
substantially increased small dense granules.  
　　The ringed LB exhibited that the presence of the 
ﬁlaments were dominant over that of the small dense 
granules in the light zone of the ring, and vice versa in 
the dark zone of the ring.
Discussion
　　It is known that approximately 48% of the cases of 
LD result from mutations in the EPM2A gene, which 
encodes a protein of 331 amino acids, called laforin, 
with a dual-specificity phosphatase domain and a 
carbohydrate-binding domain.  Laforin binds glycogen 
and can dephosphorylate both phosphoserine/
phosphothreonine and phosphotyrosine substrates, as 
well as complex carbohydrates（Minassian et al, 1998; 
Serratosa et al, 1999; Knecht et al, 2010）.   About 40% 
of Lafora cases result from mutations in the EPM2B 
gene, which encodes a protein called malin, an E3 
ubiquitin ligase of 395 amino acids with a RING ﬁnger 
domain at the N-terminus and six NHL domains in the 
C-terminal region（Chan et al, 2003; Ganesh et al, 
2006; Gometz-Abad et al, 2005; Knecht et al, 2010; 
Delgado-Escueta, 2007）.  
　　LB, deposits of abnormally branched, insoluble 
glycogen-polymers（i.e. polyglucosans）invariably form 
in neurons, liver, heart and other tissue cells in every 
patient with LD, so LB are the pathognomonic change 
for LD, and its hallmark as well.  LB are known to 
consist of 80-93% polyglucosans similar to amylopectin 
and 6% protein（Yokoi et al, 1968 ; Sakai et al, 1970）. 
LB are decorated by anti-ubiquitin antibodies, 
suggesting accumulations of undegraded proteins. 
Thus, LD may be a disorder of both carbohydrate 
metabolism and protein clearance（Knecht et al, 2010）. 
To elucidate what kind of organella and why they are 
involved in the formation of LD should lead us to 
understand the mechanisms of the morphogenesis of 
LB and some clue to the measures against LB generation. 
　　Most EM studies reported so far are those on LB 
in the developed phase, while those in the early and 
developing phases are very limited in number（Cajal et al, 
1974; Collins et al, 1968; Oyanagi, 1992; Vanderhaeghen, 
1971）.  In order to investigate the mechanisms of LB 
morphogenesis, it is necessary to observe LB in the 
early and developing phases in detail.  Therefore, 
cerebral cortical LB were classiﬁed into 3 phases, i.e. 
early, developing and developed phases, based on the 
evolution, as has been described above.  
Interpretation of the results of the present study
　　The fine filaments consisting of LB in the early 
and developing phases measure approximately 6nm in 
diameter, whereas those of LB in the developed phase 
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measure about 8nm in diameter.  This may be explained 
that with the lapse of time（ageing of LB）the fine 
filaments slightly increase in thickness and hardness 
probably due to an increase in hyperphosphorylation 
and polymerization of the glycogen.  These filaments 
and the dense granules are known to be digested by 
amylolytic enzymes（α-amylase and γ-amylase）
completely or incompletely, probably depending on the 
age of LB（Nikaido et al, 1971 Gambetti et al, 1971）. 
This indicates that both the ﬁne ﬁlaments and the small 
dense granules together with their aggregates are of 
polyglucosans that are abnormal ﬁne ﬁlaments made up 
of insoluble glucose-polymers.  The ﬁnding that there 
was a lack of mitochondria in the deep area around the 
center of LB may imply that the area lacks energy or 
does not need to use much energy.  In addition, 
intermingling with the filaments and the dense 
granules there were many small pieces of rER and 
polysomes in the LB.  This may indicate that some 
protein synthesis is taking place inside LB in the 
developing phase.  Presence of a number of lysosomes 
and multivesicular bodies may imply that some 
misfolded proteins and/or insoluble glucose polymers 
are degraded inside LB in the developing phase.  
　　It may be necessary to consider what factors are 
involved in the core or ring formation of cored or 
ringed LB.  Most of the LB in the developed phase are 
cored LB or homogeneous LB（light-pink or dark-
pink）.  EM observations revealed that the parts of LB 
which consisted of only the ﬁlaments stained light-pink 
with PAS staining.   EM of the light-pink homogeneous 
LB demonstrated that the entire area of the LB 
consisted only of compactly intermingled filaments 
innumerably increased in number, associated with a 
paucity of the small dense granules.  In contrast, the 
dark-pink homogeneous LB were demonstrated that 
the entire area of the LB consisted of intermingled 
filaments innumerably increased in number plus 
substantial amount of small dense granules deposited 
all over the LB.  Generally speaking, the more the 
dense granules deposited, the darker the homogeneous 
LB became.  It was concluded that if the part of LB 
stained more intensely, the part had more deposition 
of the small dense granules or their aggregates.  
On the molecular basis for LB generation : mainly on 
the functions of laforin
　　The molecular basis for the formation of LB, 
which has long been believed unknown, is now being 
elucidated rapidly.  Nomally, misfolded and long-lived 
proteins are targeted by laforin for degradation through 
the UPS and aggresomes are disposed of via autophagy-
lysosome（A-L）pathway.  In Lafora cells, however, this 
will not happen because there is loss of function of the 
protein laforin or malin due to the gene mutation（s）.  
It is known that the majority of the laforin gene mutations 
found in LD patients results in lack of phosphatase 
activity, absence of binding to glycogen and lack of 
interaction with R5（Fernandez-Sanchez et al, 2003;  
Solaz-Fuster, 2008）.   Normal glycogen is soluble in 
the cellular environment.  Laforin dephosphorylates 
glycogen and preserves its solubility（Tagliabracci et al, 
2007）.  In tissue cells in LD, however, deficiency of 
laforin leads to hyperphosphorylation of glycogen and 
then generation of insoluble glycogen-polymers in vivo
（Tagliabracci et al, 2007）.  Mutations of laforin that 
disable the glycogen binding domain also eliminate its 
ability to dephosphorylate glycogen（Tagliabracci et al, 
2007）.  Therefore, in cells in LD with laforin or malin 
gene mutation（s）glycogen is prone to be hyperphosphorylated 
and become insoluble polymers.  Normally such large 
and insoluble glycogen aggregates are subject to 
clearance via A-L pathway, whereas in cells in LD the 
insoluble glycogen aggregates will not be disposed but 
will remain and accumulate and increase in size to form 
aggresomes for a long period of time and may become 
toxic, leading to cell death.
Mainly on the functions of malin
　　Malin is known to interact with laforin and recruits 
to aggresomes upon proteasome inhibition and degrades 
misfolded proteins（Mittal et al, 2007; Rao et al, 2010）. 
So malin interacts with and ubiquitinates laforin, 
leading to its degradation when laforin is misfolded due 
to gene mutation（s）（Gentry et al, 2005）.　Similarly 
malin and laforin, together with Hsp70 as a functional 
complex, suppress the cellular toxicity of misfolded 
proteins and promote their degradation through the UPS
（Garyali et al, 2009）.  Proteasomal dysfunction and 
cell death frequently occurs in the mutant malin-over-
expressed cells（Rao et al, 2010）.  Malin is unstable, 
and aggregate-prone protein and co-chaperone CHIP 
can modulate its stability（Rao et al, 2010） Laforin is a 
physiologic substrate of malin, an E3-ubiquitin ligase 
whose activitiy is necessary to prevent neurodegenerative 
diseases that involve formation of neuroproteinacious 
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inclusion bodies（Gentry et al, 2005）.  Malin-laforin 
complex is a novel player in the neuronal response to 
misfolded proteins which could be potential therapeutic 
targets for neurodegenerative disorders associated with 
cytotoxic proteins（Garyali et al, 2009）.  
On the dysfunction of autophagy and failure of 
autophagic clearance of aggresomes 
　　The efficient management of misfolded protein 
aggregates is known to be essential for cell viability and 
requires 3 interconnected pathways:（1）the molecular 
chaperone machinery that assists protein folding,（2）
the proteasome pathway that degrades misfolded 
proteins,  and（3）the aggresomal pathway that 
sequesters and delivers toxic protein aggregates to 
autophagy for clearance（Criado et al, 2011）.  As for 
insoluble glycogen aggregates, the A-L pathway is 
considered to target them for clearance.  
　　Recently, Criado et al,（2011）demonstrated that 
the dysfunction of autophagy occurs as a consequence 
of the lack of laforin-malin complexes in malin-
deﬁcient mice.  Because the dysfunction of autophagy 
precedes other pathological manifestations, they 
propose that decreased autophagy plays a primary role 
in the formation of LB and it is critical in LD 
pathogenesis.  Decreased autophagy results in the 
failure of autophagic clearance of aggresomes.  Hence 
LB are a kind of aggresomes formed by hyperproduced 
polyglucosans and misfolded proteins which are 
recognized and polyubiquitinated by an E3 ubiquitin-
protein ligase such as parkin.  Adaptor proteins which 
may include histone deacetylase 6, ataxin-3, and 
ubiquilin-1, link the polyubiquitinated proteins to the 
dynein motor complex for retrograde transport to the 
aggresome（Olzmann et al, 2008; Aguado et al, 2010）.   
　　Accordingly, we are undertaking the veriﬁcation of 
their proposal by means of functional-structural analyses
（i.e. functional EM and immunocytochemistry）of the 
brain tissue and cells in Lafora disease.   Individual 
steps in the aggresome（LB formation）-autophagy 
pathway of LD may be potentially targeted for 
therapeutic intervention strategies.  
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ラフォラ病の脳病理：形成途上期ラフォラ小体の微細構造変化
吉　村　教　暤１）
１）弘前医療福祉大学 脳病理学・病態神経学
　　〒 036-8102 弘前市小比内 3-18-1
要　　　旨
ラフォラ病（LD）は常染色体劣性遺伝性の糖代謝障害による進行性の脳変性症で、病理学的には脳等
の広範な実質細胞に出現するポリグルコサン（Lafora小体 ; LB）を特徴とする。LD患者の約 90%は
EPM2A（laforin）または EPM2B（malin）の変異で発症することが最近明らかになった。LBの超微構
造変化の発達期別の記載はない。本研究は形態変化の背後にある分子発症機序に関わる所見を捉える
ことを目的に、既報１剖検例の脳組織のLBを発達期別に主に電顕的に観察した。病変形成早期では疎
らに、途上期では密に、枝分かれ少ない、不規則な微細線維と小密顆粒が多数出現し、終了期では小
密顆粒の集積による芯の形成とその外側にやや放射状に並ぶ細線維が観察された。最近、laforin-malin 
complex の欠乏がautophagyの障害を引き起こし、それがLB形成に最も重要なを働きをしていることが
明らかにされた。laforin-malin complex 異常とautophagy障害によるaggresome 除去障害について考察し
た。結論として、形成途上期LBの微細構造変化はLBのみならずLDの分子機序に連鎖した重要所見と
みなせる。
キーワード： 発達途上期 LB、微細構造変化、ポリグルコサン、ラフォリンとマリン
　　　　　　アグリソームとオートファジー
